U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case

The Supreme Court’s decision to hear the case over Medicare-related 340B cuts to hospitals surprised many observers. Oral arguments are scheduled for Nov. 30, with a decision not likely until the spring.

The U.S. Supreme Court has announced the cases it will take up this fall and 340B will be on the plate. The court recently posted its hearings schedule for the months of October through December and will hear oral

Read More »

“The Biggest Crisis Since 340B’s Inception:” 340B Report Leader Provides Input in New Podcast

In a new podcast, 340B Report Publisher and CEO Ted Slafsky provides input on key 340B challenges as well as some predictions.

The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report CEO and Publisher Ted Slafsky tells “The Future of

Read More »

North Carolina Enacts PBM Oversight Law Protecting Most 340B Covered Entities

North Carolina Gov. Roy Cooper (D) recently signed into law a new bill that gives some 340B covered entities protection from so-called discriminatory reimbursement cuts and restrictive contracting terms. Photo credit: Gov. Roy Cooper's office via Twitter.

North Carolina Gov. Roy Cooper (D) signed into law yesterday a bill that imposes greater oversight of pharmacy benefit managers and protects most categories of 340B entities from so called discriminatory reimbursement and contracting practices.

Please

Read More »

As Hospital Recertification Deadline Nears, 340B Eligibility Challenges Appear Not to Be Widespread for Now

The COVID-19 pandemic’s impact on hospitals’ eligibility for 340B could become an issue beginning later this year, industry observers say.

With the deadline for hospitals to recertify their eligibility for 340B drug discounts arriving on Monday, it appears most facilities will remain qualified—at least for now.

Please Login or Become a Paid Subscriber to View this

Read More »

Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug

Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline

Passing a federal law to stem rising drug prices would have a modest effect on the U.S. prescription drug pipeline, a new CBO analysis finds.

Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in

Read More »

House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates. A whistleblower is pursuing a similar case against Lilly.

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.

Read More »

Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy

Drug manufacturer Merck is defending and hospital groups are condemning the drug company's decision to impose mandatory conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.

 

Please Login or Become a Paid

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report